Facility-based Sleep Studies for Obstructive Sleep Apnea
Medical necessity criteria for facility-based PSG, split-night studies, CPAP/BiPAP titration, and titration PSG for hypoglossal nerve stimulation for non-Medicare Health Net plans; affects adult members (≥18 years).
Added criteria section IV to include titration PSG for hypoglossal nerve stimulation (HNS).
Expanded scope of policy statement I to include split-night studies and clarified home APAP/HSAT related criteria.
Added criteria sections II and III for repeat facility-based PSG/split-night studies and facility-based titration.
Coverage Criteria for Facility-based PSG and Titration
Initial Therapy
Covered when ALL of the following are met:
see section I.A
see section I.B items 1–9
see I.B.9.a and I.B.9.b
Repeat Studies
Covered when ALL of the following are met:
see section II.A
see section II.B
see section II.C items 1–9
Facility-based titration (CPAP/BiPAP)
Covered when ONE of the following is met:
see III.A
see III.B
HNS Titration PSG
Covered when the following is met:
see IV
Not Supported
Not supported
Coverage criteria structure and updates
Policy includes multiple numbered criteria sections governing when facility-based PSG is covered.
Full decision logic not present in these chunks.
Actigraphy testing alone is not supported for diagnosis of obstructive sleep apnea. The policy explicitly lists CPT 95803 (Actigraphy testing) as a code that does not support coverage because actigraphy by itself does not provide sufficient evidence for OSA diagnosis. (See Coding/Exclusions.)
The policy contains a heading indicating there are CPT codes that do not support coverage; specific exclusions by CPT are called out elsewhere in the document under the coding/exclusions section.
When home sleep apnea testing (HSAT) is appropriate and adequate (for example, patients with high pretest probability of moderate–severe uncomplicated OSA without significant comorbidities or suspected non‑respiratory sleep disorders), facility-based polysomnography is not necessary. The policy directs preference for HSAT in suitable patients and excludes facility-based PSG when HSAT provides valid results.
The policy revisions removed prior Epworth Sleepiness Scale–based criteria (I.B.8.b.i) during the update. This indicates the policy no longer relies on the Epworth Sleepiness Scale alone for coverage decisions and providers should not expect the scale to substitute for the documented clinical criteria now required.
Coding and Billing
| 95807 | Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist. |
| 95808 | Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist. |
| 95810 | Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist. |
| 95811 | Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist. |
| 95803 | Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording). |
| CPT codes that do not support coverage | Document headings indicate there are CPT codes listed that do not support coverage; specific codes are referenced in the policy coding section. |
| L38307 | Local coverage determination: hypoglossal nerve stimulation for the treatment of obstructive sleep apnea (CMS LCD referenced) |
| L36902 | Local coverage determination: polysomnography and other sleep studies (CMS LCD referenced) |
| L33718 | Local coverage determination: positive airway pressure (PAP) devices for the treatment of obstructive sleep apnea (CMS LCD referenced) |
Provider Requirements and Actions
Prior Authorization Required
Prior authorization required when requesting facility-based polysomnography (PSG), split-night study, or facility-based CPAP/BiPAP titration. Limit repeat facility-based PSG/split-night studies to two or fewer studies per rolling year unless clinically justified per policy criteria (see repeat study indications). Titration PSG for hypoglossal nerve stimulation (HNS) requires scheduling 3–6 months after device implantation and may require prior authorization.
- Prior auth applies to facility-based PSG, split-night studies, and facility-based titration (CPAP/BiPAP)
- Repeat facility-based PSG/split-night studies: ≤2 per rolling year (unless meeting repeat-study indications)
- Titration PSG for HNS: performed 3–6 months post-implantation
Denial Triggers
Requests for facility-based testing may be denied when home sleep apnea testing (HSAT) is appropriate, available, and not attempted; when criteria for facility testing are not met; when documentation is incomplete; or when CPT codes submitted do not support coverage.
- Denial likely if HSAT is appropriate/available but not attempted without documented reason
- Denial when member does not meet criteria I or II or when requested study exceeds allowed frequency limits
- Denial when submitted CPT codes are on the list of codes that do not support coverage
Documentation Required
Include comprehensive medical record documentation with requests: clinical indication (symptoms/signs), prior HSAT results (if any), details of prior APAP/HSAT trials including downloaded compliance data when claiming failure of APAP, and documentation supporting inability to use HSAT when claimed.
- Clinical notes documenting suspected OSA signs/symptoms
- Prior HSAT reports or explanation if HSAT was not performed
- Downloaded device data demonstrating APAP/CPAP trial and reasons for failure or intolerance
- Documentation of attempts to obtain/perform HSAT or reason HSAT is not available
Documentation Supporting Indications for Facility Testing
When claiming HSAT is inappropriate or not feasible, provide specific supporting documentation that the member has one or more conditions that interfere with HSAT accuracy or safety (examples listed below). The policy requires evidence for these indications; vague statements without supporting clinical data may result in denial.
- Examples of conditions that support facility-based testing: chronic opioid use; low pretest probability concerns where HSAT sensitivity is insufficient; mission-critical occupation where on-duty sleep risk is unacceptable; BMI ≥50 kg/m2; moderate-to-severe chronic pulmonary disease; congestive heart failure NYHA class III–IV; significant non-respiratory sleep disorder (e.g., parasomnia) or hypoventilation syndrome
- If prior HSAT was negative/inadequate, include the HSAT report and explanation of inadequacy
- If claiming inability to operate HSAT equipment, document specific functional limitations or lack of available assistance
Step Therapy / Preferred Sequence
Step therapy expectations: a trial of home APAP/HSAT is preferred and should be attempted when appropriate prior to facility-based titration. Facility-based titration is covered when HSAT is not appropriate or when there is documented diagnostic or therapeutic failure of HSAT/APAP (including objective downloaded compliance data).
- Preferred pathway: attempt home APAP/HSAT when clinically appropriate before facility titration
- Facility-based titration covered if HSAT inappropriate or if there is documented failure of HSAT/APAP (include objective device data)
- Exceptions apply (see policy criteria I.B for conditions that make HSAT inappropriate)
Background and Scope
Obstructive sleep apnea (OSA) is characterized by recurrent upper airway collapse during sleep leading to symptoms such as daytime sleepiness and snoring. Polysomnography (PSG) is the gold standard diagnostic test and involves continuous monitoring of physiologic parameters including sleep staging, respiratory flow, respiratory effort, pulse oximetry, and other signals interpreted by a clinician. PSG is used for diagnosis, titration of positive airway pressure, and evaluation of other sleep disorders. For select patients with high pretest probability of uncomplicated OSA, home sleep apnea testing (HSAT) may be an appropriate alternative, but HSAT measures fewer physiologic variables and can under-detect events in certain populations or when significant comorbidities are present.
Definitions
Revision History and Policy Changes
Added Criteria IV to include titration polysomnography (PSG) for hypoglossal nerve stimulation (HNS); clarified language in I.B.6 and I.B.7 and updated background and coding/references; included 'non‑Medicare' verbiage in Criteria V.
Updated scale criteria and added I.B.8.b.ii.c (diagnosis of hypertension); made minor rewording in Criteria I, I.A., and I.B.3 for clarity and removed Epworth Sleepiness Scale from I.B.8.b.i.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.